Obesity market news — August 17, 2026
The oral race reached Europe commercially. On August 10 the UK medicines regulator authorised Eli Lilly's orforglipron, sold as Foundayo, for weight management and for type-2 diabetes, making Britain the first country in Europe to approve it. In ATTAIN-1 the 36 mg dose produced average weight loss of 12.4 percent at 72 weeks; in ATTAIN-2, in patients with type-2 diabetes, 10.5 percent alongside an average 1.8 percentage-point fall in HbA1c. The commercially decisive detail is not the approval but what follows it: private prescriptions are expected within weeks, while NHS reimbursement requires a separate NICE appraisal that typically takes twelve to eighteen months, so funded access is unlikely before late 2027.
Novo answered with a number that deserves reading carefully. In a Reuters interview published on August 13, chief executive Mike Doustdar said the Wegovy pill currently holds about 90 percent of the US oral GLP-1 market, partly on the strength of better weight-loss data than Lilly's Foundayo, and argued that obesity will not be a winner-take-all contest because patients want optionality. Both halves of that are worth separating. The strategic argument is reasonable. The 90 percent figure is company-stated, no independent breakdown was published alongside it, and it describes a market a direct competitor has only just entered - a share measured before the race properly started.
Affordability moved from background condition to binding constraint. A Baringa analysis reported in the UK found that the roughly 1,200 pounds a year a GLP-1 costs is only offset by lower grocery spending for the highest earners: someone with 39,000 pounds of discretionary income saves about 481 pounds a year on food, and it takes 97,500 pounds of discretionary income before grocery savings reach 1,200. A partner at the firm called it a driver of inequality; the press framing was a regressive tax on being thin. These are advisory and market-research figures, not clinical data. The same wall appears in the United States from a different direction: reporting on the hormonal condition PMOS found insurers routinely refuse GLP-1 cover as off-label, leaving patients facing 250 to over 1,000 dollars a month instead of 25 to 50 with approval.
Eli Lilly (LLY): The MHRA authorised orforglipron, branded Foundayo, on August 10 for weight management in adults with a BMI of 30 or above, or 27 to 30 with at least one weight-related comorbidity, and for glycaemic control in inadequately controlled type-2 diabetes. The UK is the first country in Europe to authorise it; the EU application remains under review. Private prescriptions are expected within weeks, but NHS funding depends on a NICE appraisal that usually runs twelve to eighteen months. The US list price is about 499 dollars a month. For Lilly this converts a US oral franchise into a European commercial one, but only for patients paying privately in the first instance.
Novo Nordisk (NVO): Chief executive Mike Doustdar told Reuters in an interview published on August 13 that the oral Wegovy holds roughly 90 percent of the US oral GLP-1 market, and that obesity will not become a winner-take-all contest because patients want a choice of formats. He also said a roughly even split between tablets and injections would be a good outcome, and confirmed that CagriSema remains planned for 2027. The share figure is a company statement without a published independent breakdown, and it covers a period in which Lilly's oral rival was only beginning to build volume. Novo is defending ground lost to Zepbound in a market analysts expect to exceed 100 billion dollars a year by 2030.
Eli Lilly (LLY): Separately, on August 12 Lilly filed six lawsuits against US businesses it accuses of selling black-market retatrutide: Aesthetic Envy Cosmetic Centers, Astra LLC, Legendary Peptides, Striker Pharmacy, Texas Peptides and Lone Star Peptide Co. Retatrutide, the triple GLP-1, GIP and glucagon agonist, is still in Phase 3 and approved by no regulator anywhere for human use. Lilly says sellers label the material research use only while marketing it for injection, and that supply often comes from unregulated foreign manufacturers. The company has reported more than 200 entities to the FDA, the Department of Justice, state attorneys general and licensing boards, and has called on platforms and payment processors to act. An unapproved asset now has its own illegal market ahead of approval.
Altimmune (ALT): The second quarter, reported on August 12, was the one flagged here a week earlier as a cash-runway test, and it passed. Altimmune closed the quarter with 519 million dollars in cash, equivalents and investments, and said this funds the company through the 52-week PERFORMA MASH readout expected in 2029. Alongside the PERFORMA Phase 3 start and the positive RECLAIM Phase 2 result in alcohol use disorder, the company also completed enrolment in the RESTORE Phase 2 trial in alcohol-associated liver disease. Pemvidutide carries FDA Breakthrough Therapy designation on the 24-week IMPACT Phase 2b data. Three parallel indications on a funded balance sheet is a materially stronger position than the market assumed a month ago.
Baringa: Two reports this week measured the same wall from opposite sides. In the UK, a Baringa analysis found that the roughly 1,200 pounds annual cost of a GLP-1 is offset by lower grocery spending only for the highest earners: 481 pounds of food savings at 39,000 pounds of discretionary income, and 97,500 pounds needed before savings match the drug. In the US, reporting on the hormonal condition PMOS found insurers routinely deny cover because the use is off-label, leaving patients at 250 to over 1,000 dollars a month against 25 to 50 with approval. Neither is a clinical finding. Together they describe the constraint that increasingly determines who actually starts and stays on treatment.
PMOS: An Associated Press report on August 15 described a small but growing set of trials suggesting GLP-1 medicines improve core features of PMOS, the hormonal condition formerly called polycystic ovary syndrome: irregular periods, elevated testosterone and insulin resistance. In a study published in June in Fertility and Sterility, eight of eleven participants who completed the trial lost at least 10 percent of body weight, with a median loss of about 42 pounds and a median testosterone fall of 52 percent; six had more periods and four returned to monthly cycles. The numbers are very small, no GLP-1 is approved for the condition, and independent reviewers rate the certainty of the data as low. PMOS affects roughly one in eight women worldwide, more than 170 million people, which makes the coverage question consequential well beyond this dataset.
Nestle: Reuters reported on August 17 that Nestle is using artificial intelligence to analyse clinical research and identify nutrient combinations for products aimed at GLP-1 users, according to chief technology officer Stefan Palzer. The company already sells a Boost shake marketed with 35 grams of protein for muscle health during weight loss, a mocha Boost shot aimed at people on these medicines, and has added collagen to its Vital Proteins line for skin, hair and nail concerns linked to rapid weight loss. The specific health benefits were not substantiated by clinical trials cited in the announcement, and nutrition specialists note that conventional foods can supply the same nutrients more cheaply. The signal worth tracking is structural rather than clinical: a consumer-goods category is forming around the drug class.
Viking, Zealand, Structure, Amgen: A quiet week across the rest of the tracked field, with no new data or regulatory steps reported. Viking's Phase 3 VANQUISH programme for subcutaneous VK2735 remains fully enrolled with the oral Phase 3 guided to start in the fourth quarter. Structure Therapeutics is still guided to begin the aleniglipron Phase 3 in the third quarter, which is now. Zealand's petrelintide continues towards Phase 3 with Roche, and Amgen's MariTide remains the programme that determines whether it stays a credible third force. Each of these becomes materially more interesting once Foundayo's European launch shows what an oral commercial ramp actually looks like.